Phase I/II Clinical Study on the Safety and Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen as Neoadjuvant Therapy for Children and Adolescents With Intermediate/High-Risk Rhabdomyosarcoma
Latest Information Update: 18 Jun 2024
At a glance
- Drugs Pucotenlimab (Primary)
- Indications Rhabdomyosarcoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 18 Jun 2024 New trial record